Human Abuse Liability Design & Execution Issues Important in Controlling Experimental Conditions

The Goring is London's Quintessentially English Luxury Hotel. For over a century it has welcomed Heads of State, Presidents, World Leaders and Royalty. The great and the good, the famous and the infamous have walked the corridors and enjoyed the sophistication and discretion of this great hotel.

Join PBR for an evening of knowledge sharing and discussion, where we will be investigating the clinical aspects of conducting human abuse liability studies. The discussion will focus on when drugs in development may need to be assessed for abuse potential and appropriate methodology for assessment of abuse liability potential.

We will be -

-Exploring the various components of a human abuse liability study

- Familiarising with the types of drugs that may be required by the FDA to undergo a human abuse liability study

- Attempting to understand the challenges of conducting a human abuse liability study

- Reviewing CNS and neurology compounds

Who should attend:

- CEO
- CMO
- CSO
- Heads of R&D
- Therapeutic Area Heads
- Clinical Trial Managers

Speaker:

Dr. Lynn Webster

Vice President of Scientific Affairs, PRA

President, American Academy of Pain Medicine